One of the biggest growth narratives in the pharmaceutical industry right now is about weight loss medications. Glucagon-like peptide-1 (GLP-1) agonists such as Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are becoming ever more popular among diabetes and obesity care patients.

All of these medications are made by just two companies: Novo Nordisk and Eli Lilly (NYSE: LLY). For now, Novo Nordisk is the 800-pound gorilla in the GLP-1 arena. But Lilly has made significant strides over the last couple of years, and I think its momentum is about to be supercharged.

Let's dig into Lilly's latest move concerning Zepbound, its blockbuster drug for chronic weight management, and assess why now could be a lucrative time to scoop up some shares.

Continue reading

Source Fool.com